Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Cancer Sweden

US FDA stands firm with new trial arm for EpiCept's Ceplene in AML

This article was originally published in Scrip

Executive Summary

Following a meeting with the US FDA, EpiCept has confirmed it will have to include an interleukin-2 (IL-2) monotherapy arm in its additional Phase III trial investigating its lead drug candidate, Ceplene (histamine dihydrochloride), in combination with a low-dose IL-2 for the remission maintenance and prevention of relapse of patients with acute myeloid leukaemia (AML) in first complete remission. Scrip understands that the company now hopes to submit an amended protocol by year end.

Table

View full table

Topics

Related Companies

Tags:
Cancer Sweden
Latest Headlines

BridgeBio Spins Out Cancer Arm With $200m Fundraise

Emergex Goes To Battle Against ‘The Nasties’

Finance Watch: Venture Rounds Trend Toward The High End

The UK’s Cancer Vaccine Partnership With BioNTech Is Another First – But Can It Deliver?

See All
UsernamePublicRestriction

Register

SC014419

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By